Tandem Diabetes Care Reports Q2 2026 Sales of $254.6M, Gross Margin Improves to 57%, Reaffirms Full-Year Guidance
TNDM sits 79% above its 52-week low of $9.98.
Summary
Tandem Diabetes Care reported Q2 2026 sales of $254.6 million, a 6% increase, with gross margin improving to 57%. The company reaffirmed its full-year 2026 guidance and highlighted key regulatory and product milestones, including a 510(k) submission for Tandem Mobi tubeless capability.
Key Events · Earnings and Guidance · TNDM
-
Q2 2026 Financial Results
Worldwide sales rose 6% to $254.6 million, with U.S. sales up 5% to $179.3 million and international sales up 7% to $75.3 million. Gross margin expanded 460 basis points to 57%, and GAAP operating loss narrowed to $13.8 million from $51.8 million a year ago.
-
Full-Year 2026 Guidance Reaffirmed
The company reaffirmed its 2026 sales guidance of $1.065 billion to $1.085 billion, gross margin of 56% to 57%, and adjusted EBITDA margin of 5% to 6%. Non-cash charge guidance was reduced from $100 million to $85 million.
-
Strategic and Regulatory Milestones
Submitted a 510(k) to the FDA for Tandem Mobi tubeless capability. Received FDA clearance and CE Mark for Control-IQ+ use in pregnancy, and CE Mark for type 2 diabetes. Launched Dexcom G7 15-day sensor compatibility and Abbott FreeStyle Libre 3 Plus sensor in Europe. Began international rollout of Tandem Mobi.
-
Improved Profitability Trajectory
Adjusted EBITDA turned positive at $6.4 million (3% of sales) compared to negative $1.8 million a year ago. The reduction in expected non-cash charges for 2026 signals lower stock-based compensation and depreciation, improving the path to GAAP profitability.
Analysis · TNDM · Industrial Applications And Services
Tandem Diabetes Care delivered a solid quarter with 6% sales growth and a 460-basis-point gross margin expansion to 57%, driving a significantly narrower operating loss. The company reaffirmed its full-year 2026 guidance, signaling confidence in its commercial strategy and product pipeline. The submission of a 510(k) for the Tandem Mobi tubeless capability and multiple regulatory clearances expand the addressable market and strengthen the competitive position. The reduction in expected non-cash charges improves the earnings outlook. This earnings report provides a positive update on the company's turnaround, with improving profitability and strategic milestones that support the investment thesis.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNDM was trading at $17.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.98 to $29.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.